目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources

Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Myelodysplastic Syndrome Drugs Market Variables, Trends, & Scope
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. Myelodysplastic Syndrome Drugs Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape

Chapter 4. Myelodysplastic Syndrome Drugs Market: Product Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Myelodysplastic Syndrome Drugs Market: Product Movement Analysis, 2023 & 2030 (USD Million)
4.3. Chemotherapy
4.3.1. Chemotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Immune Treatments
4.4.1. Immune Treatments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Stem Cell Transplant
4.5.1. Stem Cell Transplant Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Other Treatment Types
4.6.1. Other Treatment Types Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Myelodysplastic Syndrome Drugs Market: Application Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Myelodysplastic Syndrome Drugs Market: Route of Administration Movement Analysis, 2023 & 2030 (USD Million)
5.3. Oral
5.3.1. Oral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Parenteral
5.4.1. Parenteral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Myelodysplastic Syndrome Drugs Market: End Use Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Myelodysplastic Syndrome Drugs Market: End Use Movement Analysis, 2023 & 2030 (USD Million)
6.3. Hospitals
6.3.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Clinics
6.4.1. Clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Other
6.5.1. Other Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Myelodysplastic Syndrome Drugs Market: Regional Estimates & Trend Analysis
7.1. Myelodysplastic Syndrome Drugs Market Share, By Region, 2023 & 2030 (USD Million)
7.2. North America
7.2.1. North America Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.2. U.S.
7.2.2.1. U.S. Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.3. Canada
7.2.3.1. Canada Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.4. Mexico
7.2.4.1. Mexico Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3. Europe
7.3.1. Europe Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.2. UK
7.3.2.1. UK Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.3. Germany
7.3.3.1. Germany Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.4. France
7.3.4.1. France Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Asia Pacific
7.4.1. Asia Pacific Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.2. China
7.4.2.1. China Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.3. Japan
7.4.3.1. Japan Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.4. India
7.4.4.1. India Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.5. South Korea
7.4.5.1. South Korea Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.6. Australia
7.4.6.1. Australia Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Latin America
7.5.1. Latin America Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.2. Brazil
7.5.2.1. Brazil Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Middle East and Africa
7.6.1. Middle East and Africa Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.2. Saudi Arabia
7.6.2.1. Saudi Arabia Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.3. UAE
7.6.3.1. UAE Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.4. South Africa
7.6.4.1. South Africa Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Company Heat Map Analysis
8.4. Company Profiles
8.4.1. Celgene Corporation
8.4.1.1. Participant’s Overview
8.4.1.2. Financial Performance
8.4.1.3. Product Benchmarking
8.4.1.4. Recent Developments/ Strategic Initiatives
8.4.2. Otsuka Pharmaceutical Co. Ltd
8.4.2.1. Participant’s Overview
8.4.2.2. Financial Performance
8.4.2.3. Product Benchmarking
8.4.2.4. Recent Developments/ Strategic Initiatives
8.4.3. Amgen Inc.
8.4.3.1. Participant’s Overview
8.4.3.2. Financial Performance
8.4.3.3. Product Benchmarking
8.4.3.4. Recent Developments/ Strategic Initiatives
8.4.4. Teva Pharmaceutical Industries Ltd.
8.4.4.1. Participant’s Overview
8.4.4.2. Financial Performance
8.4.4.3. Product Benchmarking
8.4.4.4. Recent Developments/ Strategic Initiatives
8.4.5. Sun Pharmaceutical Industries Limited
8.4.5.1. Participant’s Overview
8.4.5.2. Financial Performance
8.4.5.3. Product Benchmarking
8.4.5.4. Recent Developments/ Strategic Initiatives
8.4.6. Takeda Pharmaceutical Company Ltd
8.4.6.1. Participant’s Overview
8.4.6.2. Financial Performance
8.4.6.3. Product Benchmarking
8.4.6.4. Recent Developments/ Strategic Initiatives
8.4.7. Mylan N.V.
8.4.7.1. Participant’s Overview
8.4.7.2. Financial Performance
8.4.7.3. Product Benchmarking
8.4.7.4. Recent Developments/ Strategic Initiatives
8.4.8. Cipla Pharmaceutical Limited
8.4.8.1. Participant’s Overview
8.4.8.2. Financial Performance
8.4.8.3. Product Benchmarking
8.4.8.4. Recent Developments/ Strategic Initiatives
8.4.9. Onconova Therapeutics
8.4.9.1. Participant’s Overview
8.4.9.2. Financial Performance
8.4.9.3. Product Benchmarking
8.4.9.4. Recent Developments/ Strategic Initiatives
8.4.10. Hikma Pharmaceuticals PLC
8.4.10.1. Participant’s Overview
8.4.10.2. Financial Performance
8.4.10.3. Product Benchmarking
8.4.10.4. Recent Developments/ Strategic Initiatives